Pharmacology Quiz: Beta 2 Agonists
20 questions · exam conditions
0:00
Beta 2 AgonistsQuestion 1 of 20

A 19-year-old competitive swimmer with a history of isolated exercise-induced bronchoconstriction (EIB) requires prophylaxis. They do not have persistent asthma symptoms. Which of the following is the most appropriate first-line recommendation for use prior to exercise?

A single dose of salmeterol 60 minutes before exercise.
Daily maintenance therapy with a formoterol/budesonide inhaler.
A single dose of albuterol 15-30 minutes before exercise.
A single dose of tiotropium 30 minutes before exercise.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Beta 2 Agonists

Practice Beta 2 Agonists in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Beta 2 Agonists, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A 19-year-old competitive swimmer with a history of isolated exercise-induced bronchoconstriction (EIB) requires prophylaxis. They do not have persistent asthma symptoms. Which of the following is the most appropriate first-line recommendation for use prior to exercise?

  1. A single dose of salmeterol 60 minutes before exercise.
  2. Daily maintenance therapy with a formoterol/budesonide inhaler.
  3. A single dose of albuterol 15-30 minutes before exercise. (correct answer)
  4. A single dose of tiotropium 30 minutes before exercise.
Explanation: For isolated EIB, the preferred prophylactic treatment is a short-acting beta-2 agonist (SABA) like albuterol taken shortly before exercise. Salmeterol (LABA) has a slow onset and is not ideal. Daily ICS/LABA is not indicated for isolated EIB without persistent asthma. Tiotropium (a LAMA) is not first-line therapy for EIB.

Question 2

A 62-year-old patient with COPD is initiated on inhaled salmeterol. At a follow-up visit, they report frequent palpitations. While the intended therapeutic effect is beta-2 agonism, this adverse effect is most likely due to a dose-dependent stimulation of:

  1. Beta-1 adrenergic receptors in the myocardium. (correct answer)
  2. Beta-2 adrenergic receptors in peripheral venous capacitance vessels.
  3. Nicotinic receptors at the cardiac ganglia causing a reflex response.
  4. Alpha-2 adrenergic receptors in the presynaptic nerve terminal.
Explanation: Although considered 'selective,' beta-2 agonists can lose their selectivity at higher concentrations and stimulate beta-1 adrenergic receptors, which are abundant in the heart. Stimulation of myocardial beta-1 receptors leads to increased heart rate and contractility, causing palpitations. The other options describe effects not primarily responsible for this adverse reaction.

Question 3

A 58-year-old female with severe COPD is admitted for an acute exacerbation. Her baseline serum potassium is 3.3 mEq/L due to chronic diuretic use. She is started on continuous nebulized albuterol. Which of the following is the most critical to monitor due to a potential pharmacodynamic interaction?

  1. An acute decrease in serum potassium. (correct answer)
  2. The development of metabolic acidosis.
  3. The onset of acute renal failure.
  4. A significant increase in diastolic blood pressure.
Explanation: Beta-2 agonists stimulate the Na+/K+-ATPase pump, which drives potassium from the extracellular to the intracellular space, leading to hypokalemia. In a patient who is already hypokalemic, this effect can be profound and lead to dangerous cardiac arrhythmias. This is the most immediate and life-threatening concern. While lactic acidosis can occur with very high doses, the risk posed by worsening hypokalemia is more critical here.

Question 4

A patient with persistent asthma who is prescribed only an albuterol inhaler reports that they are now using it 4-5 times a day and feel it is 'not working as well.' While receptor downregulation contributes, this clinical scenario most critically indicates:

  1. The patient has developed a psychological dependence on the inhaler's motor action.
  2. The albuterol has likely expired and lost its chemical stability and potency.
  3. The patient's underlying airway inflammation is inadequately controlled. (correct answer)
  4. The patient's beta-2 receptors have become permanently desensitized to all agonists.
Explanation: Increased use of a short-acting beta-2 agonist (SABA) is a key indicator of worsening asthma control. SABAs only treat the symptom (bronchoconstriction) but do not address the underlying cause (inflammation). The need for more frequent SABA use signals that the inflammation is not controlled and that anti-inflammatory therapy, such as an inhaled corticosteroid (ICS), is required.

Question 5

An 80-year-old male with severe COPD receives three back-to-back nebulized treatments with albuterol. An ECG performed shortly after shows flattened T waves and the appearance of prominent U waves. This finding is most likely indicative of which adverse drug effect?

  1. Hypermagnesemia
  2. Hypokalemia (correct answer)
  3. Hypercalcemia
  4. Metabolic acidosis
Explanation: High-dose beta-2 agonist therapy causes a shift of potassium from the extracellular to the intracellular compartment. This can lead to acute hypokalemia. The classic ECG findings of hypokalemia include flattened T waves, ST-segment depression, and the appearance of a U wave. This electrolyte disturbance can predispose the patient to cardiac arrhythmias.

Question 6

A patient with well-controlled, moderate persistent asthma on a medium-dose ICS/LABA inquires about stopping the ICS component and continuing only the LABA, as they 'feel fine now.' Which of the following describes the most significant and likely consequence of this action?

  1. A gradual increase in airway hyperresponsiveness due to uncontrolled underlying inflammation. (correct answer)
  2. An immediate and severe rebound bronchoconstriction upon cessation of the inhaled corticosteroid.
  3. A rapid development of tolerance to the LABA, rendering it ineffective within several days.
  4. A paradoxical increase in systemic adverse effects from the LABA, such as tremor and palpitations.
Explanation: The patient feels well precisely because the ICS is controlling the underlying inflammation. The LABA only manages the symptom of bronchoconstriction. If the ICS is stopped, the inflammation will return unchecked. This leads to a gradual increase in airway hyperresponsiveness, worsening asthma control, and placing the patient at high risk for a severe exacerbation. This is the central tenet of modern asthma management.

Question 7

A 55-year-old patient with type 2 diabetes and asthma is started on a high-dose ICS/LABA regimen. At a follow-up, his HbA1c has increased significantly. While the ICS can contribute, which physiologic effect of the LABA component also directly contributes to hyperglycemia?

  1. Increased insulin resistance in skeletal muscle.
  2. Direct inhibition of pancreatic beta-cell insulin secretion via stimulation of alpha-2 receptors.
  3. Decreased renal clearance of glucose due to beta-2 mediated effects on renal blood flow.
  4. Stimulation of beta-2 receptors in the liver, promoting glycogenolysis and gluconeogenesis. (correct answer)
Explanation: When you encounter questions about drug-induced hyperglycemia, think systematically about how different receptor systems affect glucose metabolism. Both ICS and LABA components can raise blood sugar, but through different mechanisms. LABAs work by stimulating beta-2 adrenergic receptors throughout the body, not just in the lungs. In hepatic tissue, beta-2 receptor activation triggers a cascade that promotes both glycogenolysis (breakdown of stored glycogen) and gluconeogenesis (creation of new glucose from non-carbohydrate sources). This directly increases hepatic glucose output, contributing to hyperglycemia - making option D correct. Option A is incorrect because LABAs don't significantly affect insulin sensitivity in skeletal muscle. While beta-2 stimulation can influence muscle metabolism, the primary glycemic effect comes from hepatic glucose production, not peripheral insulin resistance. Option B misidentifies both the receptor type and location. LABAs stimulate beta-2 receptors, not alpha-2 receptors. Additionally, pancreatic beta-cells are more responsive to alpha-2 stimulation (which would inhibit insulin), but this isn't the mechanism by which LABAs affect glucose. Option C incorrectly focuses on renal glucose handling. While beta-2 receptors can influence renal blood flow, the kidney's role in glucose clearance isn't the primary mechanism for LABA-induced hyperglycemia. The effect is much more pronounced from increased hepatic glucose production. Remember: Beta-2 agonists have systemic effects beyond bronchodilation. Always consider hepatic glucose metabolism when evaluating drug-induced hyperglycemia, especially with sympathomimetic agents.

Question 8

A patient in status asthmaticus receives multiple high doses of nebulized albuterol. The nurse notes the patient has developed a fine tremor in their hands. This adverse effect is primarily mediated by the stimulation of which of the following?

  1. Beta-1 receptors in the sinoatrial node.
  2. Beta-2 receptors in skeletal muscle. (correct answer)
  3. Alpha-1 receptors in peripheral vasculature.
  4. Muscarinic M3 receptors in the central nervous system.
Explanation: Skeletal muscle tremor is a common side effect of beta-2 agonists. It is caused by the direct stimulation of beta-2 adrenergic receptors located on skeletal muscle cells. Stimulation of beta-1 receptors primarily causes tachycardia. Alpha-1 and muscarinic receptors are not directly involved in this specific adverse effect of albuterol.

Question 9

When comparing the adverse effect profiles of inhaled albuterol (SABA) versus inhaled salmeterol (LABA) used at appropriate therapeutic doses and frequencies for their respective indications, which statement is most accurate?

  1. Salmeterol is more likely to cause significant acute hypokalemia due to its longer duration of action.
  2. Albuterol is associated with a higher risk of oropharyngeal candidiasis when used frequently.
  3. Both agents can cause tremor and tachycardia, with the highest risk during acute, high-dose SABA administration. (correct answer)
  4. Salmeterol monotherapy carries a lower risk of asthma-related mortality than as-needed SABA monotherapy.
Explanation: Tachycardia and tremor are class effects for all beta-2 agonists. However, the clinical situation most associated with these effects is the administration of multiple, high doses of a SABA (like albuterol) to treat an acute exacerbation. LABAs cause these effects too, but typically to a lesser degree with standard maintenance dosing. Candidiasis is related to ICS, not beta-agonists. Acute hypokalemia is a risk of high-dose SABA. LABA monotherapy has a higher mortality risk in asthma.

Question 10

A physician is choosing a LABA to add to an ICS for a patient with asthma. Which statement accurately differentiates the pharmacokinetic property of salmeterol from formoterol that is most relevant to its use in an acute setting?

  1. Formoterol has a significantly longer half-life than salmeterol, providing more sustained bronchodilation.
  2. Salmeterol has a more rapid onset of action, making it a better choice than formoterol for urgent relief.
  3. Formoterol has a rapid onset of action similar to albuterol, whereas salmeterol has a slower, delayed onset. (correct answer)
  4. Salmeterol has higher lipid solubility, allowing it to bypass first-pass metabolism more effectively.
Explanation: A key difference between these two common LABAs is their onset of action. Formoterol has a rapid onset (within minutes), similar to SABAs. Salmeterol has a much slower onset (15-30 minutes). This is why salmeterol is never appropriate for any type of rescue, whereas combination inhalers with formoterol are sometimes used in specific 'single maintenance and reliever therapy' (SMART) regimens.

Question 11

A patient with moderate persistent asthma is prescribed a fixed-dose fluticasone/salmeterol inhaler for maintenance and an albuterol inhaler for rescue. The patient asks, 'Since salmeterol is a stronger, long-acting version of albuterol, can I just use an extra puff of my maintenance inhaler when I have an attack?' Which is the most accurate counseling point?

  1. No, because salmeterol has a very slow onset of action and will not provide rapid relief during an acute attack. (correct answer)
  2. No, because using extra doses will quickly lead to adrenal suppression from the high dose of fluticasone.
  3. Yes, that is acceptable for mild attacks, but you should still use albuterol for more severe breathing problems.
  4. No, because salmeterol is less selective for lung receptors than albuterol, causing more cardiac side effects.
Explanation: The most critical reason this patient should not use their fluticasone/salmeterol inhaler for rescue is the slow onset of action of salmeterol (15-30 minutes). Acute asthma attacks require a medication with a rapid onset (1-5 minutes), such as albuterol. Relying on salmeterol would dangerously delay effective bronchodilation. The other reasons are either incorrect or less critical than the onset of action.

Question 12

A 45-year-old patient with persistent asthma is well-managed on a daily salmeterol/fluticasone inhaler. They present to the urgent care clinic with acute wheezing and shortness of breath after exposure to cold air. Which of the following is the most appropriate immediate intervention?

  1. Administering albuterol via a nebulizer. (correct answer)
  2. Administering a second dose of their salmeterol/fluticasone inhaler.
  3. Instructing the patient to double the frequency of their maintenance inhaler for the next 24 hours.
  4. Initiating oral prednisone without an inhaled bronchodilator.
Explanation: The patient is experiencing an acute bronchospasm, which requires a short-acting beta-2 agonist (SABA) for rapid relief. Albuterol is a SABA and is the standard of care for rescue therapy. Salmeterol is a long-acting beta-2 agonist (LABA) with a slow onset of action and is not appropriate for acute relief. Increasing the maintenance inhaler dose is not for acute rescue, and while oral steroids might be needed, immediate bronchodilation is the priority.

Question 13

A patient with asthma reports waking up with coughing and wheezing three nights per week, despite using their albuterol inhaler as needed for daytime symptoms. According to treatment guidelines, which modification to their regimen is most appropriate for gaining long-term control?

  1. Instructing the patient to use their albuterol inhaler prophylactically every night before bedtime.
  2. Adding a daily combination inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA). (correct answer)
  3. Switching from albuterol to levalbuterol for as-needed use to achieve better nocturnal control.
  4. Prescribing a short, tapering course of oral corticosteroids to suppress nocturnal symptoms.
Explanation: Nocturnal awakenings due to asthma are a sign of uncontrolled persistent asthma. The appropriate step-up therapy is to add a controller medication. A combination ICS/LABA is a preferred treatment for controlling persistent symptoms, including nocturnal awakenings. Prophylactic SABA use indicates a need for better control, not a solution. Levalbuterol offers no significant advantage in this context. Oral steroids are for acute exacerbations, not chronic management.

Question 14

Formoterol is a long-acting beta-2 agonist (LABA) with a rapid onset of action comparable to albuterol. Despite its rapid onset, why is formoterol not recommended as a standalone rescue inhaler for asthma?

  1. Its extended duration of action can lead to an accumulation of tolerance if used frequently for rescue.
  2. It primarily stimulates extrapulmonary beta-2 receptors, making it less potent for bronchodilation than albuterol.
  3. Its use as a monotherapy rescue agent masks inflammation and is associated with an increased risk of asthma-related death. (correct answer)
  4. It has a higher affinity for beta-1 receptors than albuterol, leading to an unacceptable rate of tachycardia.
Explanation: The contraindication against LABA monotherapy in asthma applies to all LABAs, regardless of their onset of action. The fundamental risk is that providing long-acting bronchodilation without addressing inflammation can lead to a worsening of the underlying disease and an increased risk of severe exacerbations and death. Therefore, even a rapid-onset LABA like formoterol should not be used as a standalone rescue agent.

Question 15

A patient with asthma reports waking up with coughing and wheezing three nights per week, despite using their albuterol inhaler as needed for daytime symptoms. According to treatment guidelines, which modification to their regimen is most appropriate for gaining long-term control?

  1. Instructing the patient to use their albuterol inhaler prophylactically every night before bedtime.
  2. Adding a daily combination inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA). (correct answer)
  3. Switching from albuterol to levalbuterol for as-needed use to achieve better nocturnal control.
  4. Prescribing a short, tapering course of oral corticosteroids to suppress nocturnal symptoms.
Explanation: Nocturnal awakenings due to asthma are a sign of uncontrolled persistent asthma. The appropriate step-up therapy is to add a controller medication. A combination ICS/LABA is a preferred treatment for controlling persistent symptoms, including nocturnal awakenings. Prophylactic SABA use indicates a need for better control, not a solution. Levalbuterol offers no significant advantage in this context. Oral steroids are for acute exacerbations, not chronic management.

Question 16

A 19-year-old competitive swimmer with a history of isolated exercise-induced bronchoconstriction (EIB) requires prophylaxis. They do not have persistent asthma symptoms. Which of the following is the most appropriate first-line recommendation for use prior to exercise?

  1. A single dose of salmeterol 60 minutes before exercise.
  2. Daily maintenance therapy with a formoterol/budesonide inhaler.
  3. A single dose of albuterol 15-30 minutes before exercise. (correct answer)
  4. A single dose of tiotropium 30 minutes before exercise.
Explanation: For isolated EIB, the preferred prophylactic treatment is a short-acting beta-2 agonist (SABA) like albuterol taken shortly before exercise. Salmeterol (LABA) has a slow onset and is not ideal. Daily ICS/LABA is not indicated for isolated EIB without persistent asthma. Tiotropium (a LAMA) is not first-line therapy for EIB.

Question 17

A patient in status asthmaticus receives multiple high doses of nebulized albuterol. The nurse notes the patient has developed a fine tremor in their hands. This adverse effect is primarily mediated by the stimulation of which of the following?

  1. Beta-1 receptors in the sinoatrial node.
  2. Beta-2 receptors in skeletal muscle. (correct answer)
  3. Alpha-1 receptors in peripheral vasculature.
  4. Muscarinic M3 receptors in the central nervous system.
Explanation: Skeletal muscle tremor is a common side effect of beta-2 agonists. It is caused by the direct stimulation of beta-2 adrenergic receptors located on skeletal muscle cells. Stimulation of beta-1 receptors primarily causes tachycardia. Alpha-1 and muscarinic receptors are not directly involved in this specific adverse effect of albuterol.

Question 18

The use of a long-acting beta-2 agonist (LABA) as monotherapy for the treatment of asthma is contraindicated. What is the primary pathophysiologic reason for this black box warning?

  1. LABAs cause rapid and irreversible downregulation of beta-2 receptors, nullifying the effect of rescue inhalers.
  2. LABAs provide symptomatic relief that can mask underlying airway inflammation, allowing it to progress untreated. (correct answer)
  3. LABAs have a high incidence of causing life-threatening cardiovascular events in patients with asthma.
  4. LABAs are potent inducers of CYP3A4, leading to failure of other asthma medications such as corticosteroids.
Explanation: The primary danger of LABA monotherapy in asthma is that they improve symptoms (bronchodilation) without treating the underlying inflammation. This can give the patient and provider a false sense of security while the inflammatory process worsens, increasing the risk of a severe, potentially fatal asthma attack. The increased risk of asthma-related death is linked to this masking of inflammation.

Question 19

Formoterol is a long-acting beta-2 agonist (LABA) with a rapid onset of action comparable to albuterol. Despite its rapid onset, why is formoterol not recommended as a standalone rescue inhaler for asthma?

  1. Its extended duration of action can lead to an accumulation of tolerance if used frequently for rescue.
  2. It primarily stimulates extrapulmonary beta-2 receptors, making it less potent for bronchodilation than albuterol.
  3. Its use as a monotherapy rescue agent masks inflammation and is associated with an increased risk of asthma-related death. (correct answer)
  4. It has a higher affinity for beta-1 receptors than albuterol, leading to an unacceptable rate of tachycardia.
Explanation: The contraindication against LABA monotherapy in asthma applies to all LABAs, regardless of their onset of action. The fundamental risk is that providing long-acting bronchodilation without addressing inflammation can lead to a worsening of the underlying disease and an increased risk of severe exacerbations and death. Therefore, even a rapid-onset LABA like formoterol should not be used as a standalone rescue agent.

Question 20

A patient with persistent asthma who is prescribed only an albuterol inhaler reports that they are now using it 4-5 times a day and feel it is 'not working as well.' While receptor downregulation contributes, this clinical scenario most critically indicates:

  1. The patient has developed a psychological dependence on the inhaler's motor action.
  2. The albuterol has likely expired and lost its chemical stability and potency.
  3. The patient's underlying airway inflammation is inadequately controlled. (correct answer)
  4. The patient's beta-2 receptors have become permanently desensitized to all agonists.
Explanation: Increased use of a short-acting beta-2 agonist (SABA) is a key indicator of worsening asthma control. SABAs only treat the symptom (bronchoconstriction) but do not address the underlying cause (inflammation). The need for more frequent SABA use signals that the inflammation is not controlled and that anti-inflammatory therapy, such as an inhaled corticosteroid (ICS), is required.